TLDR New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
Inflammatory skin diseases (ISDs) were linked to the production of disease-relevant cytokines via the JAK-STAT pathway, which was crucial for various cytokines and growth factors. Targeting this pathway gained significant attention, leading to the development of new drugs to inhibit JAK and STAT molecules. Although only a few JAK inhibitors were FDA approved, others were in development. Notably, oral JAK1/JAK2 inhibitors like ruxolitinib and baricitinib induced hair regrowth in Alopecia areata patients, and the JAK1/JAK3 inhibitor tofacitinib showed significant improvement in psoriasis. This approach offered an alternative to neutralizing single cytokines with antibodies.
28 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
48 citations,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
139 citations,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
701 citations,
August 2014 in “Nature medicine” Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
489 citations,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
1 citations,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
New hair regrowth therapies show promise but need more research.
56 citations,
January 2021 in “Clinical and Experimental Medicine” The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
